Wall Street analyst estimates for Agilent Technologies, Inc. (A): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS).
Analyst Consensus
| Strong Buy | 1 |
| Buy | 32 |
| Hold | 7 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 41 |
| Avg rating (1-5) | 0.81 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-23 | $1.72 | ||
| 2026-08-26 | $1.62 | $1.49 | +8.7% |
| 2026-05-27 | $1.49 | $1.41 | +5.7% |
| 2026-02-25 | $1.36 | $1.37 | -0.7% |
| 2025-11-24 | $1.59 | $1.58 | +0.4% |
| 2025-08-27 | $1.37 | $1.37 | +0.0% |
| 2025-05-28 | $1.31 | $1.26 | +4.0% |
| 2025-02-26 | $1.31 | $1.28 | +2.3% |
Valuation Ratios
| P/E Ratio | 29.51 |
| Price / Book | 5.75 |
| EV / EBITDA | 22.65 |
| Dividend Yield | 0.67% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.20B | $4.47B | $4.91B | $5.16B | $5.34B | $6.32B | $6.85B | $6.83B | $6.51B | $6.95B |
| Cost of Revenue | $2.00B | $2.06B | $2.23B | $2.36B | $2.50B | $2.91B | $3.13B | $3.37B | $2.98B | $3.31B |
| Gross Profit | $2.20B | $2.41B | $2.69B | $2.81B | $2.84B | $3.41B | $3.72B | $3.46B | $3.54B | $3.64B |
| Research & Development | $329.0M | $339.0M | $385.0M | $404.0M | $495.0M | $441.0M | $467.0M | $481.0M | $479.0M | $455.0M |
| Selling, General & Admin | $1.25B | $1.23B | $1.37B | $1.46B | $1.50B | $1.62B | $1.64B | $1.63B | $1.52B | $1.71B |
| Operating Expenses | $1.58B | $1.57B | $1.78B | $1.86B | $1.99B | $2.06B | $2.10B | $2.12B | $2.05B | $2.16B |
| Operating Income | $615.0M | $841.0M | $904.0M | $941.0M | $846.0M | $1.35B | $1.62B | $1.35B | $1.49B | $1.48B |
| EBITDA | $863.0M | $1.10B | $1.23B | $1.23B | $1.23B | $1.76B | $1.91B | $1.70B | $1.87B | $1.83B |
| Interest Expense | $72.0M | $79.0M | $75.0M | $74.0M | $78.0M | $81.0M | $84.0M | $95.0M | $96.0M | $112.0M |
| Pre-tax Income | $544.0M | $803.0M | $946.0M | $919.0M | $842.0M | $1.36B | $1.50B | $1.34B | $1.52B | $1.44B |
| Income Tax | $82.0M | $119.0M | $630.0M | -$152.0M | $123.0M | $150.0M | $250.0M | $99.0M | $232.0M | $132.0M |
| Net Income | $460.0M | $684.0M | $316.0M | $1.07B | $719.0M | $1.21B | $1.25B | $1.24B | $1.29B | $1.30B |
| EPS | $1.42 | $2.12 | $0.98 | $3.41 | $2.33 | $3.98 | $4.19 | $4.22 | $4.44 | $4.59 |
| EPS (Diluted) | $1.40 | $2.10 | $0.97 | $3.37 | $2.30 | $3.94 | $4.18 | $4.19 | $4.43 | $4.57 |
| Shares Outstanding (Diluted) | $329.0M | $326.0M | $325.0M | $318.0M | $312.0M | $307.0M | $300.0M | $296.0M | $291.0M | $284.0M |
Price
| Price | $153.69 |
| Market Cap | $43.4B |
| Exchange | NYSE |
| Country | US |
Related companies: ALC · BDX · CAH · EW · HLN · INSM · IQV
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of A: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks